Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Gains from Sales and Divestitures: 2018-2024

Historic Gains from Sales and Divestitures for Rocket Pharmaceuticals (RCKT) over the last 5 years, with Dec 2024 value amounting to $722,471.

  • Rocket Pharmaceuticals' Gains from Sales and Divestitures rose 40.31% to $825,320 in Q3 2025 from the same period last year, while for Sep 2025 it was $825,320, marking a year-over-year increase of 40.31%. This contributed to the annual value of $722,471 for FY2024, which is 77.02% up from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Gains from Sales and Divestitures of $722,471 as of FY2024, which was up 77.02% from $408,119 recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' Gains from Sales and Divestitures registered a high of $722,471 during FY2024, and its lowest value of $7,051 during FY2020.
  • Its 3-year average for Gains from Sales and Divestitures is $389,852, with a median of $408,119 in 2023.
  • Data for Rocket Pharmaceuticals' Gains from Sales and Divestitures shows a peak YoY spiked of 947.37% (in 2023) over the last 5 years.
  • Over the past 4 years, Rocket Pharmaceuticals' Gains from Sales and Divestitures (Yearly) stood at $7,051 in 2020, then reached $38,966 in 2022, then spiked by 947.37% to $408,119 in 2023, then soared by 77.02% to $722,471 in 2024.